Protagen Applying UNIarray Platform for Biogen's MS Drug Research | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – German biotech firm Protagen today announced it will be using its UNIarray platform to support Biogen Idec's efforts in finding therapies for multiple sclerosis.

Under the terms of the agreement, the UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS. Protagen will also apply its expertise in autoantibody research to the alliance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.